검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Syngeneic Lymphocytes (CD4+, Syngeneic Lymphocytes, Syngeneic Lymphocytes (CD4+) Cultured with OKT3 (Ortho) and Interleukin-2 (Chiro) National Human Genome Research Ins…·Acquired Immunodeficiency Syndrome 71 trials |
|---|---|
Overview Program | Syngeneic Lymphocytes (CD4+) Cultured with OKT3 (Ortho) and Interleukin-2 (Chiro |
Overview Company | National Human Genome Research Institute (NHGRI) |
Overview Modality | ANTIBODY |
Overview Target | Acquired Immunodeficiency Syndrome |
Overview Indication | Acquired Immunodeficiency Syndrome; HIV Infection |
Overview Phase | PHASE_1 |
Overview Status | ACTIVE |
MoA Mechanism | remains poorly understood |
MoA Biomarker | PD-1⁺ TIM-3⁺ CD8⁺ and CD4⁺ T cells were analyzed by flow |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse, In vitro |
PK/PD Experiment | PD |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse, In vitro |
Toxicology Major finding | Chemo-Immunotherapy, a Combination Approach for the Treatment of HER2-Positive Breast Cancer in a Mouse Model.. The discovery of tumor-associated antigens has been a significant milestone for cancer therapy as the current conventional therapies (radiotherapy, chemotherapy) were found to be insufficient in terms of cancer treatment. Human epidermal growth factor receptor (HER2) is a tumor-associate… |
Clinical PFS | 48 |
Clinical OS | 60 |
Clinical Result source | ClinicalTrials.gov NCT00245037 |
Clinical Data Tier / Score | A · 36 |
Clinical Program phase | PHASE_1 |
Clinical Clinical sync | 2026년 7월 9일 (5일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Syngeneic Lymphocytes (CD4+, Syngeneic Lymphocytes, Syngeneic Lymphocytes (CD4+) Cultured with OKT3 (Ortho) and Interleukin-2 (Chiro) National Human Genome Research Ins…·Acquired Immunodeficiency Syndrome 71 trials |
|---|---|
Overview Program | Syngeneic Lymphocytes (CD4+) Cultured with OKT3 (Ortho) and Interleukin-2 (Chiro |
Overview Company | National Human Genome Research Institute (NHGRI) |
Overview Modality | ANTIBODY |
Overview Target | Acquired Immunodeficiency Syndrome |
Overview Indication | Acquired Immunodeficiency Syndrome; HIV Infection |
Overview Phase | PHASE_1 |
Overview Status | ACTIVE |
MoA Mechanism | remains poorly understood |
MoA Biomarker | PD-1⁺ TIM-3⁺ CD8⁺ and CD4⁺ T cells were analyzed by flow |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse, In vitro |
PK/PD Experiment | PD |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse, In vitro |
Toxicology Major finding | Chemo-Immunotherapy, a Combination Approach for the Treatment of HER2-Positive Breast Cancer in a Mouse Model.. The discovery of tumor-associated antigens has been a significant milestone for cancer therapy as the current conventional therapies (radiotherapy, chemotherapy) were found to be insufficient in terms of cancer treatment. Human epidermal growth factor receptor (HER2) is a tumor-associate… |
Clinical PFS | 48 |
Clinical OS | 60 |
Clinical Result source | ClinicalTrials.gov NCT00245037 |
Clinical Data Tier / Score | A · 36 |
Clinical Program phase | PHASE_1 |
Clinical Clinical sync | 2026년 7월 9일 (5일 전) |
추천 비교
추천 비교